At J&J, Q3 Pharma Performance Is Up, Rest of Business Is Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts were disappointed in J&J's overall results, but the pharma sector performed well, driven by Remicade and new product sales.
You may also be interested in...
Eli Lilly, J&J, Novartis: Emerging Markets Earnings Roundup (Part 1 of 2)
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets.
J&J vs. Merck: What Might A Remicade Settlement Look Like?
Analysts say Merck has a good chance of prevailing in arbitration over J&J's agreement with Schering to co-distribute Remicade but that the two parties may opt to settle.
J&J Pharma Hit By EU Price Cuts, Weaker Euro
Hit from EU pricing cuts is estimated at about $200 million in 2010.